Bioventus (BVS) Financials

$7.74 -0.18 (-2.27%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$7.77 +0.03 (+0.39%)

As of 07:25 AM Eastern

Annual Income Statements for Bioventus

This table shows Bioventus' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-159	-156	-34
Consolidated Net Income / (Loss)	-213	-196	-44
Net Income / (Loss) Continuing Operations	-145	-121	-44
Total Pre-Tax Income	-189	-121	-49
Total Operating Income	-167	-82	-12
Total Gross Profit	331	328	388
Total Revenue	512	512	573
Operating Revenue	512	512	573
Total Cost of Revenue	181	184	185
Operating Cost of Revenue	181	184	185
Total Operating Expenses	498	410	400
Selling, General & Admin Expense	332	304	341
Research & Development Expense	24	13	14
Depreciation Expense	9.75	8.84	7.65
Other Operating Expenses / (Income)	0.00	3.58	0.29
Impairment Charge	125	79	36
Restructuring Charge	6.78	0.84	-0.05
Other Special Charges / (Income)	1.10	0.72	1.42
Total Other Income / (Expense), net	-22	-39	-37
Interest & Investment Income	-12	-41	-39
Other Income / (Expense), net	-9.77	1.29	1.65
Income Tax Expense	-44	0.09	-5.29
Net Income / (Loss) Discontinued Operations	-69	-74	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-55	-39	-10
Basic Earnings per Share	($2.59)	($2.49)	($0.52)
Weighted Average Basic Shares Outstanding	61.39M	62.65M	64.55M
Diluted Earnings per Share	($2.59)	($2.49)	($0.52)
Weighted Average Diluted Shares Outstanding	61.39M	62.65M	64.55M
Weighted Average Basic & Diluted Shares Outstanding	78.05M	79.17M	81.94M

This table shows Bioventus' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-108	-32	-139	-3.68	-7.30	-6.10	-4.57	-24	-4.82	-0.16
Consolidated Net Income / (Loss)	-146	-45	-174	-4.73	-8.79	-7.66	-5.98	-32	-5.42	-0.32
Net Income / (Loss) Continuing Operations	-101	-21	-100	-4.73	-8.79	-7.66	-5.98	-32	-5.42	-0.32
Total Pre-Tax Income	-131	-32	-100	-4.35	-8.19	-8.41	-5.08	-39	-4.83	0.23
Total Operating Income	-127	-16	-92	6.75	2.42	1.17	5.33	-29	4.07	7.99
Total Gross Profit	85	74	74	89	79	86	88	104	94	103
Total Revenue	129	126	119	137	121	135	129	151	139	154
Operating Revenue	129	126	119	137	121	135	129	151	139	154
Total Cost of Revenue	44	52	45	48	42	49	41	48	45	51
Operating Cost of Revenue	44	52	45	48	42	49	41	48	45	51
Total Operating Expenses	211	90	166	82	76	85	83	133	89	95
Selling, General & Admin Expense	79	77	81	75	70	78	78	95	81	87
Research & Development Expense	4.61	5.95	3.77	3.40	3.02	3.26	2.60	3.99	3.81	3.25
Depreciation Expense	2.26	1.54	2.13	2.29	2.32	2.10	1.76	2.06	2.07	1.77
Impairment Charge	125	-	79	0.00	0.00	-	0.00	32	2.03	2.46
Restructuring Charge	0.58	4.62	0.32	0.62	-0.03	-0.07	0.00	0.00	0.00	-0.05
Other Special Charges / (Income)	0.28	0.28	0.29	0.24	-0.10	0.29	0.30	0.30	0.48	0.35
Total Other Income / (Expense), net	-3.72	-17	-8.11	-11	-11	-9.57	-10	-10	-8.91	-7.76
Interest & Investment Income	-3.60	-7.39	-9.69	-11	-10	-10	-10	-9.92	-9.53	-9.00
Other Income / (Expense), net	-0.12	-9.41	1.59	-0.51	-0.49	0.71	-0.06	-0.16	0.63	1.24
Income Tax Expense	-30	-11	-0.15	0.38	0.60	-0.75	0.91	-7.34	0.59	0.55
Net Income / (Loss) Attributable to Noncontrolling Interest	-37	-13	-35	-1.05	-1.49	-1.56	-1.41	-8.12	-0.60	-0.16
Basic Earnings per Share	($1.76)	($0.53)	($2.24)	($0.06)	($0.12)	($0.07)	($0.07)	($0.37)	($0.07)	($0.01)
Weighted Average Basic Shares Outstanding	61.67M	61.39M	62.12M	62.55M	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M
Diluted Earnings per Share	($1.76)	($0.53)	($2.24)	($0.06)	($0.12)	($0.07)	($0.07)	($0.37)	($0.07)	($0.01)
Weighted Average Diluted Shares Outstanding	61.67M	61.39M	62.12M	62.55M	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M
Weighted Average Basic & Diluted Shares Outstanding	77.74M	78.05M	78.27M	78.58M	78.75M	79.17M	79.61M	80.97M	81.15M	81.94M

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-67	5.13	4.62
Net Cash From Operating Activities	-14	15	39
Net Cash From Continuing Operating Activities	-11	18	39
Net Income / (Loss) Continuing Operations	-145	-121	-44
Consolidated Net Income / (Loss)	-213	-196	-44
Net Income / (Loss) Discontinued Operations	-69	-74	0.00
Depreciation Expense	55	57	50
Non-Cash Adjustments To Reconcile Net Income	153	84	46
Changes in Operating Assets and Liabilities, net	-75	-3.13	-13
Net Cash From Discontinued Operating Activities	-2.13	-2.17	0.00
Net Cash From Investing Activities	-116	16	23
Net Cash From Continuing Investing Activities	-12	27	23
Purchase of Property, Plant & Equipment	-1.48	-7.36	-1.01
Acquisitions	-10	0.00	-0.71
Divestitures	0.00	35	25
Other Investing Activities, net	-0.08	0.00	0.00
Net Cash From Discontinued Investing Activities	-105	-12	0.00
Net Cash From Financing Activities	62	-27	-55
Net Cash From Continuing Financing Activities	62	-27	-55
Repayment of Debt	-45	-91	-62
Issuance of Debt	105	64	0.00
Issuance of Common Equity	5.82	0.78	2.44
Other Financing Activities, net	-3.35	0.00	4.50
Effect of Exchange Rate Changes	0.52	0.63	-2.56

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-6.62	-2.55	15	-18	-2.56	10	-12	6.82	11	-1.49
Net Cash From Operating Activities	-0.70	5.24	2.49	11	-8.32	10	-6.01	15	10	19
Net Cash From Continuing Operating Activities	0.16	6.52	4.66	11	-8.32	10	-6.01	15	10	19
Net Income / (Loss) Continuing Operations	-101	-21	-100	-4.73	-8.79	-7.66	-5.98	-32	-5.42	-0.32
Consolidated Net Income / (Loss)	-146	-45	-174	-4.73	-8.79	-7.66	-5.98	-32	-5.42	-0.32
Depreciation Expense	14	17	16	15	14	12	12	13	12	12
Non-Cash Adjustments To Reconcile Net Income	129	15	82	-2.34	2.70	1.83	1.99	36	3.35	4.53
Changes in Operating Assets and Liabilities, net	-42	-3.46	5.92	3.27	-16	3.73	-14	-1.96	0.11	2.70
Net Cash From Investing Activities	-56	-3.40	-15	34	-2.04	-0.59	-1.00	-0.08	-0.06	24
Net Cash From Continuing Investing Activities	49	-3.40	-3.56	34	-2.04	-0.59	-1.00	-0.08	-0.06	24
Purchase of Property, Plant & Equipment	-1.65	5.16	-3.56	-1.40	-2.04	-0.37	-0.29	-0.08	-0.06	-0.57
Divestitures	-	-	-	-	-	-0.22	-	-	-	25
Net Cash From Financing Activities	51	-5.44	27	-62	8.23	-0.01	-4.24	-7.85	0.36	-43
Net Cash From Continuing Financing Activities	51	-5.44	27	-62	8.23	-0.01	-4.24	-7.85	0.36	-43
Repayment of Debt	-29	-6.52	-20	-60	-7.17	-3.83	-3.24	-8.45	-0.19	-50
Issuance of Common Equity	0.48	1.08	0.08	0.14	0.40	0.16	0.18	0.61	0.55	1.10
Other Financing Activities, net	-	-	-1.67	-1.99	-	3.66	-1.18	-	-	5.68
Effect of Exchange Rate Changes	-0.24	1.05	0.46	0.24	-0.44	0.37	-0.54	-0.42	0.47	-2.06

This table presents Bioventus' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	1,373	811	728
Total Current Assets	273	268	276
Cash & Equivalents	30	37	42
Accounts Receivable	136	123	127
Inventories, net	85	91	92
Prepaid Expenses	19	17	14
Plant, Property, & Equipment, net	27	37	27
Total Noncurrent Assets	1,073	506	421
Long-Term Investments	2.62	3.14	1.89
Goodwill	7.46	7.46	7.46
Intangible Assets	640	482	405
Other Noncurrent Operating Assets	17	13	6.51
Total Liabilities & Shareholders' Equity	1,373	811	728
Total Liabilities	960	590	542
Total Current Liabilities	304	175	210
Short-Term Debt	33	28	47
Accounts Payable	37	23	24
Accrued Expenses	112	120	136
Other Current Liabilities	3.61	4.82	3.92
Total Noncurrent Liabilities	656	414	332
Long-Term Debt	385	367	308
Noncurrent Deferred & Payable Income Tax Liabilities	2.25	1.21	0.56
Other Noncurrent Operating Liabilities	40	46	23
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	412	221	186
Total Preferred & Common Equity	325	174	148
Total Common Equity	325	174	148
Common Stock	491	494	506
Retained Earnings	-165	-322	-355
Accumulated Other Comprehensive Income / (Loss)	-0.11	0.79	-2.57
Noncontrolling Interest	87	48	38

This table presents Bioventus' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,398	887	837	811	794	792	769
Total Current Assets	271	309	261	249	266	309	299
Cash & Equivalents	34	47	29	27	25	32	43
Accounts Receivable	132	119	120	113	126	137	122
Inventories, net	77	88	96	98	97	88	90
Prepaid Expenses	28	17	15	12	18	24	17
Other Current Assets	-	38	-	-	-	28	27
Plant, Property, & Equipment, net	0.00	37	42	40	35	32	29
Total Noncurrent Assets	1,127	542	534	522	494	451	441
Long-Term Investments	13	2.62	6.54	6.86	3.21	2.09	1.93
Goodwill	15	7.46	7.46	7.46	7.46	7.46	7.46
Intangible Assets	1,056	516	505	493	471	425	415
Noncurrent Deferred & Refundable Income Taxes	0.00	-	-	-	-	6.88	7.40
Other Noncurrent Operating Assets	43	16	15	14	12	10	9.78
Total Liabilities & Shareholders' Equity	1,398	887	837	811	794	792	769
Total Liabilities	1,019	647	604	585	577	603	583
Total Current Liabilities	288	196	179	161	173	231	211
Short-Term Debt	31	41	11	20	36	57	58
Accounts Payable	19	33	41	18	19	24	17
Accrued Expenses	117	116	122	119	114	140	129
Other Current Liabilities	121	6.15	4.67	4.73	4.81	9.74	8.15
Total Noncurrent Liabilities	731	451	425	424	403	372	371
Long-Term Debt	393	404	375	375	355	345	345
Noncurrent Deferred & Payable Income Tax Liabilities	159	0.35	0.00	0.00	1.29	0.00	0.00
Other Noncurrent Operating Liabilities	178	46	50	49	47	27	26
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	379	240	233	226	217	189	187
Total Preferred & Common Equity	343	189	183	178	171	151	149
Total Common Equity	343	189	183	178	171	151	149
Common Stock	478	493	491	493	497	501	503
Retained Earnings	-133	-304	-308	-315	-326	-350	-355
Accumulated Other Comprehensive Income / (Loss)	-1.34	0.41	0.66	0.40	0.33	-0.02	0.45
Noncontrolling Interest	36	52	50	49	46	38	38

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	18.85%	0.04%	11.89%
EBITDA Growth	-367.41%	81.03%	270.01%
EBIT Growth	-1,769.85%	54.56%	87.15%
NOPAT Growth	-904.00%	51.13%	85.34%
Net Income Growth	-2,326.07%	8.33%	77.59%
EPS Growth	-1,626.67%	3.86%	79.12%
Operating Cash Flow Growth	-158.88%	213.35%	152.84%
Free Cash Flow Firm Growth	92.87%	353.99%	-27.74%
Invested Capital Growth	-9.38%	-21.83%	-14.46%
Revenue Q/Q Growth	-0.89%	1.91%	3.28%
EBITDA Q/Q Growth	-17.38%	49.32%	22.85%
EBIT Q/Q Growth	-15.13%	25.08%	41.58%
NOPAT Q/Q Growth	-8.07%	17.05%	36.29%
Net Income Q/Q Growth	-25.22%	15.98%	14.34%
EPS Q/Q Growth	-25.73%	15.59%	10.34%
Operating Cash Flow Q/Q Growth	-139.00%	50.23%	29.98%
Free Cash Flow Firm Q/Q Growth	92.63%	3.87%	153.18%
Invested Capital Q/Q Growth	-2.57%	-1.96%	-9.56%
Profitability Metrics	-	-	-
Gross Margin	64.65%	64.06%	67.72%
EBITDA Margin	-23.75%	-4.50%	6.84%
Operating Margin	-32.66%	-15.95%	-2.09%
EBIT Margin	-34.56%	-15.70%	-1.80%
Profit (Net Income) Margin	-41.67%	-38.18%	-7.65%
Tax Burden Percent	112.89%	161.53%	89.23%
Interest Burden Percent	106.79%	150.57%	475.38%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-15.11%	-8.72%	-1.57%
ROIC Less NNEP Spread (ROIC-NNEP)	-47.02%	-49.47%	-12.28%
Return on Net Nonoperating Assets (RNNOA)	-30.01%	-53.06%	-19.98%
Return on Equity (ROE)	-45.11%	-61.78%	-21.55%
Cash Return on Invested Capital (CROIC)	-5.27%	15.79%	14.02%
Operating Return on Assets (OROA)	-13.62%	-7.37%	-1.34%
Return on Assets (ROA)	-16.42%	-17.92%	-5.70%
Return on Common Equity (ROCE)	-37.40%	-48.66%	-17.04%
Return on Equity Simple (ROE_SIMPLE)	-65.61%	-112.69%	-29.63%
Net Operating Profit after Tax (NOPAT)	-117	-57	-8.39
NOPAT Margin	-22.86%	-11.17%	-1.46%
Net Nonoperating Expense Percent (NNEP)	31.91%	40.76%	10.71%
Return On Investment Capital (ROIC_SIMPLE)	-14.10%	-9.29%	-1.55%
Cost of Revenue to Revenue	35.35%	35.94%	32.28%
SG&A Expenses to Revenue	64.86%	59.31%	59.46%
R&D to Revenue	4.66%	2.62%	2.38%
Operating Expenses to Revenue	97.30%	80.01%	69.81%
Earnings before Interest and Taxes (EBIT)	-177	-80	-10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-122	-23	39
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.62	2.39	5.76
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.40	0.81	1.49
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.92	1.42	2.44
Enterprise Value to Revenue (EV/Rev)	1.32	1.60	2.10
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	30.63
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	53.26	30.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	7.89	16.04
Leverage & Solvency	-	-	-
Debt to Equity	1.01	1.79	1.91
Long-Term Debt to Equity	0.93	1.66	1.66
Financial Leverage	0.64	1.07	1.63
Leverage Ratio	2.75	3.45	3.78
Compound Leverage Factor	2.93	5.19	17.99
Debt to Total Capital	50.35%	64.10%	65.68%
Short-Term Debt to Total Capital	3.98%	4.52%	8.67%
Long-Term Debt to Total Capital	46.37%	59.58%	57.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	10.48%	7.72%	6.96%
Common Equity to Total Capital	39.17%	28.18%	27.36%
Debt to EBITDA	-3.44	-17.12	9.06
Net Debt to EBITDA	-3.17	-15.38	7.95
Long-Term Debt to EBITDA	-3.17	-15.91	7.86
Debt to NOPAT	-3.57	-6.90	-42.36
Net Debt to NOPAT	-3.29	-6.20	-37.18
Long-Term Debt to NOPAT	-3.29	-6.42	-36.77
Altman Z-Score	-0.12	0.31	1.11
Noncontrolling Interest Sharing Ratio	17.11%	21.24%	20.95%
Liquidity Ratios	-	-	-
Current Ratio	0.90	1.53	1.31
Quick Ratio	0.55	0.91	0.80
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-41	104	75
Operating Cash Flow to CapEx	-915.90%	208.42%	3,856.36%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.39	0.47	0.75
Accounts Receivable Turnover	3.92	3.96	4.58
Inventory Turnover	2.47	2.09	2.01
Fixed Asset Turnover	20.31	16.00	18.02
Accounts Payable Turnover	6.75	6.17	7.92
Days Sales Outstanding (DSO)	93.10	92.29	79.64
Days Inventory Outstanding (DIO)	147.64	174.52	181.27
Days Payable Outstanding (DPO)	54.05	59.20	46.08
Cash Conversion Cycle (CCC)	186.70	207.61	214.83
Capital & Investment Metrics	-	-	-
Invested Capital	737	576	493
Invested Capital Turnover	0.66	0.78	1.07
Increase / (Decrease) in Invested Capital	-76	-161	-83
Enterprise Value (EV)	675	817	1,202
Market Capitalization	203	415	852
Book Value per Share	$4.18	$2.20	$1.82
Tangible Book Value per Share	($4.14)	($4.02)	($3.26)
Total Capital	830	616	541
Total Debt	418	395	355
Total Long-Term Debt	385	367	308
Net Debt	385	355	312
Capital Expenditures (CapEx)	1.48	7.36	1.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-29	83	71
Debt-free Net Working Capital (DFNWC)	1.61	120	112
Net Working Capital (NWC)	-31	93	65
Net Nonoperating Expense (NNE)	96	138	35
Net Nonoperating Obligations (NNO)	324	355	307
Total Depreciation and Amortization (D&A)	55	57	50
Debt-free, Cash-free Net Working Capital to Revenue	-5.58%	16.28%	12.31%
Debt-free Net Working Capital to Revenue	0.32%	23.49%	19.56%
Net Working Capital to Revenue	-6.14%	18.05%	11.38%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.59)	($2.49)	($0.52)
Adjusted Weighted Average Basic Shares Outstanding	61.39M	62.65M	64.55M
Adjusted Diluted Earnings per Share	($2.59)	($2.49)	($0.52)
Adjusted Weighted Average Diluted Shares Outstanding	61.39M	62.65M	64.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.05M	79.17M	81.94M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-1.09	18
Normalized NOPAT Margin	-4.74%	-0.21%	3.14%
Pre Tax Income Margin	-36.91%	-23.64%	-8.57%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.16%	-3.51%	1.51%	-2.32%	-6.12%	7.62%	8.73%	10.32%	15.04%	13.45%
EBITDA Growth	-1,787.42%	-181.91%	-759.63%	145.95%	113.89%	276.83%	123.04%	-178.88%	7.77%	50.88%
EBIT Growth	-6,937.36%	-1,299.50%	-329.03%	259.43%	101.52%	107.48%	105.82%	-573.42%	144.28%	392.48%
NOPAT Growth	-12,014.52%	-396.41%	-329.17%	304.05%	101.91%	107.45%	105.79%	-535.08%	68.49%	-1,442.62%
Net Income Growth	-6,321.24%	-2,270.47%	-1,078.22%	40.97%	93.97%	82.94%	96.57%	-578.76%	38.33%	95.85%
EPS Growth	-5,766.67%	0.00%	-1,078.95%	45.45%	93.18%	86.79%	96.88%	-516.67%	41.67%	85.71%
Operating Cash Flow Growth	-106.62%	-60.02%	111.85%	267.30%	-1,086.16%	97.83%	-341.16%	40.45%	224.06%	86.25%
Free Cash Flow Firm Growth	-71.20%	111.09%	122.23%	137.65%	131.93%	147.52%	-53.43%	-97.07%	-73.25%	-55.26%
Invested Capital Growth	143.06%	-9.38%	-23.23%	-24.70%	-22.32%	-21.83%	-8.79%	-4.51%	-7.28%	-14.46%
Revenue Q/Q Growth	-8.32%	-2.20%	-5.38%	15.13%	-11.87%	12.11%	-4.41%	16.81%	-8.10%	10.56%
EBITDA Q/Q Growth	-1,438.07%	92.85%	-812.53%	128.16%	-24.41%	-8.96%	18.90%	-196.41%	203.27%	27.45%
EBIT Q/Q Growth	-3,145.25%	80.27%	-261.14%	106.89%	-69.15%	-2.60%	180.90%	-660.92%	115.92%	96.36%
NOPAT Q/Q Growth	-3,734.31%	87.67%	-488.72%	107.33%	-64.18%	-51.82%	357.25%	-651.30%	113.87%	-483.94%
Net Income Q/Q Growth	-1,718.04%	69.20%	-288.76%	97.29%	-85.82%	12.91%	21.87%	-436.81%	83.12%	94.13%
EPS Q/Q Growth	-1,500.00%	69.89%	-322.64%	97.32%	-100.00%	41.67%	0.00%	-428.57%	81.08%	85.71%
Operating Cash Flow Q/Q Growth	-123.85%	848.07%	-52.52%	333.53%	-177.03%	224.76%	-157.89%	352.49%	-31.96%	87.30%
Free Cash Flow Firm Q/Q Growth	-2.49%	112.23%	96.16%	53.07%	-13.09%	-5.15%	-63.09%	-90.39%	694.80%	58.63%
Invested Capital Q/Q Growth	-2.39%	-2.57%	-13.64%	-8.32%	0.70%	-1.96%	0.77%	-4.01%	-2.22%	-9.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	65.70%	58.96%	62.09%	65.02%	65.28%	63.73%	68.27%	68.54%	67.32%	66.82%
EBITDA Margin	-88.11%	-6.44%	-62.15%	15.20%	13.04%	10.59%	13.17%	-10.87%	12.22%	14.08%
Operating Margin	-98.58%	-12.43%	-77.32%	4.92%	2.00%	0.86%	4.11%	-19.42%	2.93%	5.20%
EBIT Margin	-98.67%	-19.91%	-75.99%	4.55%	1.59%	1.38%	4.07%	-19.53%	3.38%	6.01%
Profit (Net Income) Margin	-113.24%	-35.66%	-146.52%	-3.45%	-7.28%	-5.65%	-4.62%	-21.24%	-3.90%	-0.21%
Tax Burden Percent	111.60%	138.33%	174.16%	108.76%	107.33%	91.08%	117.87%	81.40%	112.19%	-137.07%
Interest Burden Percent	102.84%	129.50%	110.72%	-69.75%	-425.73%	-448.56%	-96.41%	133.61%	-102.81%	2.51%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	237.07%
Return on Invested Capital (ROIC)	-66.82%	-5.75%	-37.97%	2.59%	1.05%	0.47%	2.48%	-12.80%	2.01%	-7.65%
ROIC Less NNEP Spread (ROIC-NNEP)	-91.70%	-16.99%	-69.28%	-0.54%	-1.79%	-2.02%	-0.08%	-16.02%	-0.29%	-4.43%
Return on Net Nonoperating Assets (RNNOA)	-68.82%	-10.84%	-63.87%	-0.43%	-2.18%	-2.17%	-0.14%	-27.23%	-0.50%	-7.21%
Return on Equity (ROE)	-135.64%	-16.59%	-101.84%	2.16%	-1.14%	-1.70%	2.34%	-40.03%	1.51%	-14.86%
Cash Return on Invested Capital (CROIC)	-103.70%	-5.27%	3.56%	4.70%	14.85%	15.79%	11.00%	2.10%	5.23%	14.02%
Operating Return on Assets (OROA)	-49.67%	-7.85%	-37.47%	2.27%	0.73%	0.65%	2.53%	-12.87%	2.38%	4.48%
Return on Assets (ROA)	-57.01%	-14.06%	-72.24%	-1.72%	-3.31%	-2.65%	-2.87%	-14.00%	-2.74%	-0.15%
Return on Common Equity (ROCE)	-110.34%	-13.75%	-85.27%	1.81%	-0.98%	-1.34%	1.84%	-31.66%	1.19%	-11.75%
Return on Equity Simple (ROE_SIMPLE)	-49.63%	0.00%	-197.88%	-201.83%	-131.16%	0.00%	-15.86%	-36.14%	-34.40%	0.00%
Net Operating Profit after Tax (NOPAT)	-89	-11	-64	4.73	1.69	0.82	3.73	-21	2.85	-11
NOPAT Margin	-69.01%	-8.70%	-54.12%	3.45%	1.40%	0.60%	2.88%	-13.59%	2.05%	-7.13%
Net Nonoperating Expense Percent (NNEP)	24.87%	11.24%	31.31%	3.13%	2.84%	2.49%	2.56%	3.22%	2.30%	-3.21%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.32%	-	-	-	0.13%	-	-	-	-2.02%
Cost of Revenue to Revenue	34.30%	41.04%	37.91%	34.98%	34.72%	36.27%	31.73%	31.46%	32.68%	33.18%
SG&A Expenses to Revenue	61.37%	61.54%	67.91%	54.60%	57.80%	57.86%	60.57%	62.68%	58.35%	56.37%
R&D to Revenue	3.59%	4.73%	3.17%	2.48%	2.50%	2.41%	2.01%	2.64%	2.74%	2.11%
Operating Expenses to Revenue	164.29%	71.38%	139.41%	60.10%	63.27%	62.87%	64.15%	87.96%	64.39%	61.62%
Earnings before Interest and Taxes (EBIT)	-127	-25	-90	6.24	1.92	1.87	5.26	-30	4.70	9.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-113	-8.11	-74	21	16	14	17	-16	17	22
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.58	0.62	0.44	1.23	1.46	2.39	2.40	3.03	6.34	5.76
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.05	0.40	0.16	0.44	0.52	0.81	0.79	0.85	1.70	1.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.26	0.92	0.84	1.07	1.14	1.42	1.41	1.55	2.46	2.44
Enterprise Value to Revenue (EV/Rev)	1.85	1.32	1.03	1.23	1.33	1.60	1.57	1.61	2.41	2.10
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	12.07	28.14	41.92	30.63
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	53.64	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	74.87	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	53.27	35.13	65.51	53.26	119.82	77.02	44.84	30.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	20.38	19.61	6.71	7.89	12.27	72.15	45.25	16.04
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.12	1.01	1.85	1.65	1.74	1.79	1.80	2.13	2.16	1.91
Long-Term Debt to Equity	1.04	0.93	1.68	1.61	1.66	1.66	1.63	1.82	1.85	1.66
Financial Leverage	0.75	0.64	0.92	0.80	1.22	1.07	1.66	1.70	1.74	1.63
Leverage Ratio	3.37	2.75	2.73	2.71	3.65	3.45	3.67	3.86	3.82	3.78
Compound Leverage Factor	3.46	3.56	3.03	-1.89	-15.53	-15.46	-3.54	5.15	-3.93	0.10
Debt to Total Capital	52.82%	50.35%	64.96%	62.32%	63.54%	64.10%	64.28%	68.01%	68.31%	65.68%
Short-Term Debt to Total Capital	3.90%	3.98%	6.02%	1.83%	3.15%	4.52%	5.88%	9.70%	9.80%	8.67%
Long-Term Debt to Total Capital	48.92%	46.37%	58.94%	60.49%	60.38%	59.58%	58.39%	58.32%	58.51%	57.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.45%	10.48%	7.56%	8.10%	7.88%	7.72%	7.58%	6.45%	6.46%	6.96%
Common Equity to Total Capital	42.74%	39.17%	27.48%	29.58%	28.58%	28.18%	28.14%	25.54%	25.22%	27.36%
Debt to EBITDA	-4.10	-3.44	-2.38	-2.21	-8.67	-17.12	5.76	13.09	12.62	9.06
Net Debt to EBITDA	-3.64	-3.17	-2.12	-2.00	-7.93	-15.38	5.34	11.98	11.21	7.95
Long-Term Debt to EBITDA	-3.79	-3.17	-2.16	-2.14	-8.24	-15.91	5.23	11.23	10.81	7.86
Debt to NOPAT	-3.92	-3.57	-2.68	-2.42	-5.72	-6.90	35.69	-28.07	-30.61	-42.36
Net Debt to NOPAT	-3.48	-3.29	-2.38	-2.19	-5.23	-6.20	33.10	-25.69	-27.19	-37.18
Long-Term Debt to NOPAT	-3.63	-3.29	-2.43	-2.35	-5.44	-6.42	32.42	-24.07	-26.21	-36.77
Altman Z-Score	0.24	0.24	-0.01	0.46	0.48	0.64	0.67	0.51	1.20	1.20
Noncontrolling Interest Sharing Ratio	18.66%	17.11%	16.27%	16.24%	13.98%	21.24%	21.41%	20.90%	21.06%	20.95%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.94	0.90	1.57	1.46	1.55	1.53	1.53	1.33	1.41	1.31
Quick Ratio	0.58	0.55	0.84	0.83	0.87	0.91	0.87	0.73	0.78	0.80
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-534	65	128	196	170	162	60	5.74	46	72
Operating Cash Flow to CapEx	-42.51%	0.00%	69.94%	772.73%	-408.40%	2,811.38%	-2,063.57%	19,690.91%	16,118.75%	3,366.20%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.50	0.39	0.49	0.50	0.46	0.47	0.62	0.66	0.70	0.75
Accounts Receivable Turnover	4.35	3.92	4.32	3.89	4.10	3.96	4.28	4.18	4.73	4.58
Inventory Turnover	3.03	2.47	2.42	2.28	2.14	2.09	1.95	1.95	1.95	2.01
Fixed Asset Turnover	0.00	20.31	16.74	15.25	0.00	16.00	14.71	14.55	16.06	18.02
Accounts Payable Turnover	11.48	6.75	6.67	5.63	10.17	6.17	6.94	5.46	10.62	7.92
Days Sales Outstanding (DSO)	83.93	93.10	84.46	93.87	88.97	92.29	85.21	87.34	77.21	79.64
Days Inventory Outstanding (DIO)	120.42	147.64	150.92	159.79	170.61	174.52	187.43	186.73	186.89	181.27
Days Payable Outstanding (DPO)	31.79	54.05	54.70	64.84	35.89	59.20	52.62	66.82	34.36	46.08
Cash Conversion Cycle (CCC)	172.56	186.70	180.68	188.82	223.69	207.61	220.03	207.25	229.74	214.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	756	737	636	583	587	576	580	557	545	493
Invested Capital Turnover	0.97	0.66	0.70	0.75	0.75	0.78	0.86	0.94	0.98	1.07
Increase / (Decrease) in Invested Capital	445	-76	-193	-191	-169	-161	-56	-26	-43	-83
Enterprise Value (EV)	955	675	531	626	669	817	821	864	1,338	1,202
Market Capitalization	542	203	84	226	259	415	412	458	943	852
Book Value per Share	$4.43	$4.18	$2.42	$2.34	$2.26	$2.20	$2.16	$1.90	$1.84	$1.82
Tangible Book Value per Share	($9.39)	($4.14)	($4.29)	($4.21)	($4.11)	($4.02)	($3.88)	($3.53)	($3.38)	($3.26)
Total Capital	804	830	686	619	621	616	609	591	590	541
Total Debt	424	418	446	386	395	395	391	402	403	355
Total Long-Term Debt	393	385	404	375	375	367	355	345	345	308
Net Debt	377	385	396	350	361	355	363	368	358	312
Capital Expenditures (CapEx)	1.65	-5.16	3.56	1.40	2.04	0.37	0.29	0.08	0.06	0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-20	-29	107	63	81	83	103	103	102	71
Debt-free Net Working Capital (DFNWC)	14	1.61	154	93	108	120	128	135	145	112
Net Working Capital (NWC)	-17	-31	113	82	89	93	93	77	87	65
Net Nonoperating Expense (NNE)	57	34	110	9.46	10	8.47	9.71	12	8.27	-11
Net Nonoperating Obligations (NNO)	377	324	396	350	361	355	363	368	358	307
Total Depreciation and Amortization (D&A)	14	17	16	15	14	12	12	13	12	12
Debt-free, Cash-free Net Working Capital to Revenue	-3.94%	-5.58%	20.79%	12.43%	16.18%	16.28%	19.75%	19.14%	18.36%	12.31%
Debt-free Net Working Capital to Revenue	2.71%	0.32%	29.95%	18.18%	21.52%	23.49%	24.56%	25.09%	26.12%	19.56%
Net Working Capital to Revenue	-3.35%	-6.14%	21.91%	15.97%	17.62%	18.05%	17.71%	14.42%	15.71%	11.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.76)	($0.53)	($2.24)	($0.06)	($0.12)	($0.07)	($0.07)	($0.37)	($0.07)	($0.01)
Adjusted Weighted Average Basic Shares Outstanding	61.67M	61.39M	62.12M	62.55M	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M
Adjusted Diluted Earnings per Share	($1.76)	($0.53)	($2.24)	($0.06)	($0.12)	($0.07)	($0.07)	($0.37)	($0.07)	($0.01)
Adjusted Weighted Average Diluted Shares Outstanding	61.67M	61.39M	62.12M	62.55M	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	77.74M	78.05M	78.27M	78.58M	78.75M	79.17M	79.61M	80.97M	81.15M	81.94M
Normalized Net Operating Profit after Tax (NOPAT)	-0.90	-7.51	-8.99	5.33	1.61	0.97	3.94	1.96	4.61	7.52
Normalized NOPAT Margin	-0.70%	-5.97%	-7.55%	3.89%	1.33%	0.72%	3.04%	1.30%	3.32%	4.89%
Pre Tax Income Margin	-101.47%	-25.78%	-84.13%	-3.17%	-6.78%	-6.21%	-3.92%	-26.09%	-3.48%	0.15%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Bioventus' Financials

When does Bioventus's financial year end?

According to the most recent income statement we have on file, Bioventus' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bioventus' net income changed over the last 2 years?

Bioventus' net income appears to be on a downward trend, with a most recent value of -$43.83 million in 2024, falling from -$213.39 million in 2022. The previous period was -$195.63 million in 2023.

What is Bioventus's operating income?

Bioventus's total operating income in 2024 was -$11.98 million, based on the following breakdown:

Total Gross Profit: $388.23 million
Total Operating Expenses: $400.21 million

How has Bioventus revenue changed over the last 2 years?

Over the last 2 years, Bioventus' total revenue changed from $512.12 million in 2022 to $573.28 million in 2024, a change of 11.9%.

How much debt does Bioventus have?

Bioventus' total liabilities were at $542.35 million at the end of 2024, a 8.0% decrease from 2023, and a 43.5% decrease since 2022.

How much cash does Bioventus have?

In the past 2 years, Bioventus' cash and equivalents has ranged from $30.19 million in 2022 to $41.58 million in 2024, and is currently $41.58 million as of their latest financial filing in 2024.

How has Bioventus' book value per share changed over the last 2 years?

Over the last 2 years, Bioventus' book value per share changed from 4.18 in 2022 to 1.82 in 2024, a change of -56.4%.

Remove Ads

Related Companies

This page (NYSE:BVS) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Financials

Frequently Asked Questions About Bioventus' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Financials

Annual Income Statements for Bioventus

Quarterly Income Statements for Bioventus

Annual Cash Flow Statements for Bioventus

Quarterly Cash Flow Statements for Bioventus

Annual Balance Sheets for Bioventus

Quarterly Balance Sheets for Bioventus

Annual Metrics and Ratios for Bioventus

Quarterly Metrics and Ratios for Bioventus

Frequently Asked Questions About Bioventus' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools